#1 - Tim Cash - Senescent Cells: What Are They & Why/How Senolytx Is Trying To Fix Them Artwork

The Simple BioTech Podcast

Interviews with the researchers, founders, and investors of the BioTech industry. An insiders look into what is going on in the world of BioTech, from curing aging to psychedelic therapy, we interview the game changers of the industry. The unsung hero's that are moving the industry forward in a significant way. The world is going to be a vastly different place in the next 10-20 years because of what's happening in the BioTech industry right now.Human civilization will move forward farther, faster, and more significantly in the next 20 years than it has in all of human history and the Simple BioTech podcast is your personal pocket guide to all that is happening, before it happens.I'm your host. James Ruhle. I'm a serial entrepreneur and I've been following the BioTech industry as a side hobby for the past 5 years. The science of longevity is going to completely change the human experience. People will be living healthy and active lives and starting new careers at 100 years old because that will be considered middle age. Wha BioTech ultimately comes down to is improving the quality and length of life for humans.Expect 2-3 episodes monthly.Visit SimpleBioTechPodcast.com for the latest episodes, transcripts, and show notes.

All Episodes

The Simple BioTech Podcast

#1 - Tim Cash - Senescent Cells: What Are They & Why/How Senolytx Is Trying To Fix Them

March 18, 2020 • James Ruhle

Today's episode is an interview with Tim Cash, Chief Science Officer of Senolytx Therapeutics, one of the six daughter companies of David Sinclair's Life BioSciences.

In this episode Tim helps me to understand exactly why senescent cells, and the damage they cause to the human body is such an important issue we, as humans, need to fix. If you're interested in learning why and how the human body ages, you're going to love this episode.

We go over the different methods and theories behind fixing senescent cells:
senolytics, senomorphics, and utilizing the immune system to get rid of them naturally, as well as touch on how Senolytx is navigating the regulatory hurdles by focusing on Fibrosis initially, as their main target, with the broader goal of targeting aging as a whole as they progress through clinical trials.

We also go into some of the promising results Senolytx is seeing with their therapies, and Tim enlightens me on some of the most exciting things happening in BioTech right now, and where he see's things in the next 5, 10, and 15 years.

-James Ruhle, SimpleBioTechPodcast.com

Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech

If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle